T9 474.22

INTRODUCTION

Human cortical tissue can be exceedingly difficult to model in vitro. Issues of cellular survival and maintaining in vivo-like function pervade, often affecting study validity and translatability. Planar cultures have long been the standard method of growing cells in vitro, but they fail to capture the complexities of the in vivo environment. This is particularly applicable to the delicate balance of microgliamediated inflammatory responses. Three-dimensional (3D) cultures have been shown to be more physiologically relevant models of in vivo tissue. However, even they fail to fully mimic living tissue and suffer from the lack of active oxygen and nutrient transport. Lena Biosciences has developed a groundbreaking in vitro system that facilitates long-term survival of 3D cultures and significantly improves cellular metabolic function. PerfusionPal offers a simple method for simultaneously perfusing twelve statistically independent 3D cultures using only a single tube and pump. Utilizing a unique blood substitute, cultures grown in SeedEZ 3D scaffolds receive superior oxygenation, resulting in significant functional improvements and allowing for growth of denser cultures with increased longevity. Using this system, Lena Biosciences has developed a human cortical model comprising iPSC-derived neurons (acquired from BrainXell), primary astrocytes, and cells from the HMC3 microglia cell line. Both glutamatergic and GABAergic neurons were combined to generate a more accurate model. PerfusionPal enables the study of the complex interplay between pro- and anti-inflammatory responses to insult and the longterm effects of activating these pathways

METHODS

<u>Cell culture</u>

HepG2 cells and HMC3 cells (ATCC) were maintained in EMEM supplemented with 10% fetal bovine serum in a humidified incubator at 37 °C. Rat cortical cell cultures were generated by combining cells from two cortical tissue dissociations (BrainBits®, postnatal day 0 and embryonic day 18) and were cultured in Neurobasal medium supplemented with B-27 Supplement and GlutaMAX. Human cortical cultures comprising iPSC-derived neurons (Cellular Dynamics, BrainXell) and primary astrocytes (ScienCell), and HMC3 microglia cells were plated and maintained in iPSC neuronal medium or BrainXell's Cortical Neuron Complete Medium. Jurkat T cells (kindly provided by Nate Dwarshuis from the Roy lab) were maintained according to ATCC specifications. Primary human T cells (Astarte) were cultured and activated according to protocols from the Roy lab.

3D cultures were generated using Lena Biosciences' patented SeedEZ[™] scaffolds:



HepG2 cells were seeded in Matrigel® (8 mg/mL) at a density of 300,000 cells per scaffold. Cultures were allowed to gel at 37 °C for 15 minutes and subsequently transferred to Lena Biosciences' PerfusionPal system or to a multiwell plate ("Control"). Cultures in PerfusionPal were either maintained without perfusion "Static") or subjected to perfusion at a rate of 16 culture volume changes per 24 hour period ("Perfused") for the duration of the study. 2D control cultures consisted of the same number of cells plated in 24-well plates.

Human cortical cultures were plated in medium or in Matrigel[®] (8 mg/mL) into SeedEZ[™] scaffolds that had been coated with poly-D-lysine (PDL) (100 µg/mL) followed with MaxGel[™] human extracellular matrix (ECM) (1 mg/mL) (both reagents from Sigma-Aldrich) or just PDL, respectively. The total cell density was 500,000 or1,000,000 cells/scaffold with an overall cellular ratio of 2:2:1 neurons:astrocytes:microglia. Perfusion conditions were the same as for HepG2 cells.

alamarBlue Assay for Metabolic Function

After the specified number of days *in vitro* (DIV), alamarBlue reagent was added to cultures at a volume equal to 1/10 of the volume of culture medium. The cultures were returned to the incubator for a period of 30 minutes to 2 hours (depending on cell type) after which a sample of the medium from each condition was transferred to a 96-well plate and read on a Biotek Synergy 4 plate reader for fluorescence (ex/em 545/590 nm). Data (HepG2) were normalized to cell number as determined by total LDH of a set of cell density standards described below.

LDH Assay for Total and Released LDH

Prior to the addition of alamarBlue reagent, a sample of medium was taken to assess LDH release. After the alamarBlue assay, the cultures were lysed with Triton X-100 (1%) for 1 hour at 37 °C for determination of total LDH. In addition, a freshly plated set of HepG2 3D cultures with densities ranging from 200,000 – 4,000,000 cells/scaffold were lysed and used to generate a standard curve to determine cell number in each culture. A sample of medium from each condition was transferred to a 96-well plate for a colorimetric LDH assay. LDH release data were normalized to cell number.

Immunocytochemistry

The 3-D cultures were fixed with 2% paraformaldehyde for 30 minutes at room Whole cultures were incubated with primary antibody microtubuleassociated protein (MAP2) and glial fibrillary acidic protein (GFAP) from Chemicon overnight at 4°C. Cultures were incubated with the appropriate secondary antibody (Jackson ImmunoResearch) for 1 hour at room temperature. Cellular nuclei were labeled using DAPI stain (Molecular Probes). Imaging was carried out using Neurolucida software controlling a Nikon Eclipse 80i upright microscope equipped with an Optronics MicroFIRE camera.

Cell Viability Assessment

After the specified number of DIV, cultures were removed from the PerfusionPal system and were exposed to Calcein AM (in DPBS) for a period of 30 minutes at room temperature followed by multiple rinses with DPBS. Imaging was carried out using Neurolucida software controlling a Nikon Eclipse 80i upright microscope equipped with an Optronics MicroFIRE camera.

Statistical Analysis

Statistical significance was determined by One-way ANOVA and Tukey's post-hoc test or by Two-way ANOVA.



diffusion alone. Scale bars: 50µm

A perfused three-dimensional culture model of human cortical tissue

J. Vukasinovic¹, J.T. Shoemaker, M.C. LaPlaca² ¹Lena Biosciences, Inc., Atlanta, GA; ²Georgia Inst. of Technol., Atlanta, GA

This research was supported by funds from the Marcus Foundation, The Georgia Research Alliance, and the Georgia Tech Foundation through their support of the Marcus Center for Therapeutic Cell Characterization and Manufacturing (MC3M) at Georgia Tech. This work was also funded by an NIH Phase I SBIR award (1R43TR001286-01A1), an NIH Phase II SBIR award (2R44TR001286-02) and an NSF Phase I SBIR award (1549126).